Press Releases
Date Title and Summary View
Aug 14, 2017 SAN DIEGO, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that its Compensation Committee granted inducement awards pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules on July 31, 2017, August 7, 2017 and August 14, 2017 consisting of stock options to purchase an aggregate of 65,000 shares to three new employe...
Aug 9, 2017 Fosmetpantotenate (RE-024) Phase 3 trial underway in PKAN Protocol design for pivotal Phase 3 trial of sparsentan in FSGS complete; sparsentan IP estate expanded to 2030 for FSGS Second quarter revenues increased 16 percent to $39 million SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its second ...
Aug 1, 2017 SAN DIEGO (August 1, 2017) – Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, has been named by PharmaVOICE magazine to the 2017 PharmaVOICE 100 – an award that recognizes the 100 Most Inspiring People in the life sciences industry. Mr. Aselage has been acknowledged for his leadership during a ...
Jul 26, 2017 SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2017 financial results on Wednesday, August 9, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:...
Jul 25, 2017 SAN DIEGO, July 25, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been dosed in the FORT (FOsmetpantotenate Replacement Therapy) Study, an international, registrational Phase 3 clinical trial assessing the safety and efficacy of RE-024 (fosmetpantotenate) for the treatment of pantothenate kinase...
Jun 1, 2017 SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have each issued a patent covering the Company's product candidate sparsentan, which is advancing to Phase 3 clinical development for the treatment of focal segm...
May 25, 2017 Subgroup analysis from Phase 2 DUET study of sparsentan in FSGS to be presented at ERA-EDTA PKAN-ADL scale in Phase 3 FORT study of RE-024 in PKAN to be highlighted at MDS SAN DIEGO, May 25, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced upcoming presentations related to its late-stage development programs, sparsenta...
May 23, 2017 SAN DIEGO, May 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Tuesday, June 6, 2017 at 3:30 p.m. ET. A live webcast of the presentation will be available at http://ir.retrophin.com/eve...
May 4, 2017 Phase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017 Protocol development underway for pivotal Phase 3 trial of sparsentan in FSGSFirst quarter revenues rose 16 percent to $34 millionSAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its first quarter 2017 financial results and provided a corporat...
Apr 20, 2017 SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p...
Page:
1
... NextLast
= add release to Briefcase